FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: A phase II study of safety, tolerability, and anti-inflammatory activity

Lehrer Graiwer Joshua, Parmanand Singh, Amr Abdelbaky, Esad Vucic, Magnus Korsgren, Amos Baruch, Jill Fredrickson, Nick Van Bruggen, Meina T. Tang, Bjorn Frendeus, James H.F. Rudd, Frank Hsieh, Christie M. Ballantyne, Brian Ghoshhajra, Robert S. Rosenson, Michael Koren, Eli M. Roth, Daniel A. Duprez, Zahi A. Fayad, Ahmed A. Tawakol

Research output: Contribution to journalLetterpeer-review

36 Scopus citations
Original languageEnglish (US)
Pages (from-to)493-494
Number of pages2
JournalJACC: Cardiovascular Imaging
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2015

Bibliographical note

Funding Information:
Please note: This study was supported by Genentech, Inc . and BioInvent International AB . Dr. Lehrer-Graiwer is an employee of and holds stock in Global Blood Therapeutics. Dr. Singh was supported by a grant from the National Heart, Lung, and Blood Institute (5T32 HL076136). Dr. Korsgren was employed by BioInvent at the time of the study. Drs. Baruch and van Bruggen are employees of Genentech/Roche. Drs. Fredrickson and Tang are employees and stockholders of Genentech/Roche. Dr. Frendeus is an employee of BioInvent. Dr. Rudd is partly supported by the Cambridge NIHR Biomedical Research Centre . Dr. Ballantyne has received grant support and consulting fees from Genentech / Roche . Dr. Ghoshhajra has received consulting fees from Siemens. Dr. Rosenson has served on advisory boards for and has received grant support (institution) from F. Hoffman La Roche. Dr. Koren has received research grants from Roche . Dr. Roth has received consulting fees from Amgen, Sanofi, and Regeneron. Dr. Duprez has received research grants from Amgen , Sanofi , Regeneron , and Pfizer ; and has served on advisory boards for AstraZeneca and Novartis. Dr. Fayad has received grant support from Genentech / Roche . Dr. Tawakol has received grant support from Genentech / Roche ; and has received consulting fees from Genentech/Roche and BioInvent. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Lehrer-Graiwer and Singh contributed equally to this study and are co-first authors.

Cite this